More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world. But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges. Ernst & Young has been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry. We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals. So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.
Through the Ernst & Young’s Global Life Science Center, we bring together a worldwide team of industry professionals to help you achieve your potential — a team with deep experience in providing assurance, tax, transaction and advisory services specific to biotechnology companies around the globe. It’s a team that works to anticipate market trends and their implications, so you get practical advice on the right way forward for your organization. We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues specific and often unique to the biotech sector.
Whether it’s raising capital, forming the right alliances, improving operations, expanding globally or gaining insights into the market, we can give you a clear perspective on how to drive value in today’s complex, competitive and risk-driven environment.
As big pharma faces a widening growth gap, our Firepower Index highlights industry's capacity for deals in 2013 and beyond.
As serious resource constraints continue to plague the industry, how can biotech innovation be sustained? Delve into our 26th edition for key findings and insights.
Disruptive innovations and unsustainable costs are propelling life sciences companies into the behavioral change business. Learn why in our annual life sciences report.
